ZE74-0282 is a novel JAK2 JH2 domain inhibitor with promising preclinical activity in JAK2V617F mutant diseases Dec 22 Written by Sergey Kostikov Download Poster Sergey Kostikov Next Next Discovery of a novel, selective brain penetrant CDK2 inhibitor for targeted cancer therapy
ZE74-0282 is a novel JAK2 JH2 domain inhibitor with promising preclinical activity in JAK2V617F mutant diseases Dec 22 Written by Sergey Kostikov Download Poster Sergey Kostikov
